Carregant...
The effect of tafamidis on the QT(c) interval in healthy subjects
AIMS: The transthyretin (TTR) stabilizer, tafamidis, has demonstrated efficacy and safety in the treatment of TTR familial amyloid polyneuropathy (20 mg day(−1)). Tafamidis use in TTR cardiomyopathy led to the study of the potential effect of tafamidis on the QT(c) interval in healthy subjects. METH...
Guardat en:
| Publicat a: | Br J Clin Pharmacol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BlackWell Publishing Ltd
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4456124/ https://ncbi.nlm.nih.gov/pubmed/25546001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12561 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|